Literature DB >> 2036817

The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations.

F P Maesen1, R Costongs, J J Smeets, P J Brombacher, P G Zweers.   

Abstract

In a randomized, double-blind, crossover cumulative study, the individual maximal bronchodilator dosages for formoterol (F) and salbutamol (S) were assessed for their respective influence on ECG, pulse rate, and serum potassium levels in 13 patients with stable and reversible asthma. The following dosages were administered with an interval of 1 h: 12-24-48-(48)-(48) micrograms for F and 100-200-400-400-(400)-(400) micrograms for S. The study day was discontinued if pulse rate was above 140 beats min-1, a flattening of T wave on the ECG was recorded, or a maximal bronchodilation in FEV1 was observed (above 110 percent of the predicted value or an increase in FEV1 in the last two measurements below 5 percent). The maximal individual dose of F administered was 84 micrograms in six patients, 132 micrograms in three patients, 180 micrograms in three patients, and 228 micrograms in one patient. For S, the maximal individual dose was 400 micrograms in three patients, 2,200 micrograms in eight patients, 3,000 micrograms in one patient, and 3,800 micrograms in one patient. The mean maximal increase in FEV1 was 36.0 percent after F and 35.1 percent after S. Pulse rate increased from 73 to S3 beats.min-1 after F and from 75 to 84 beats.min-1 after S (both statistically significant). No pulse rate above 140 beats.min-1 was observed. In the high-therapeutic range (up to 36 micrograms of F and 6,090 micrograms of S), no changes in potassium level were observed. In still higher dosages, mean potassium level decreased from 4.16 to 3.78 mmol.L-1 after F and from 4.02 to 3.88 mmol.L-1 after S (not clinically relevant). The lowest individual potassium level recorded was 3.1 mmol.L-1. No clinically important changes in ECG were observed. In conclusion, very high doses of F and S administered from a metered dose inhaler proved to be safe for patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2036817     DOI: 10.1378/chest.99.6.1367

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

Review 1.  Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Authors:  L P Boulet
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

2.  Unsuspected coronary artery disease revealed by administration of nebulised salbutamol.

Authors:  H E Montgomery; J Gill; C W Pumphrey
Journal:  Br Heart J       Date:  1994-08

3.  Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.

Authors:  A R Guhan; S Cooper; J Oborne; S Lewis; J Bennett; A E Tattersfield
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 4.  Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.

Authors:  R A Bartow; R N Brogden
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

Review 5.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.

Authors:  Mario Cazzola; Maria G Matera; Claudio F Donner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma.

Authors:  Katayoon Najafizadeh; Hamid Sohrab Pour; Mojtaba Ghadyanee; Masoud Shiehmorteza; Masoud Jamali; Sayeed Majdzadeh
Journal:  Emerg Med J       Date:  2007-05       Impact factor: 2.740

7.  Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction.

Authors:  S Suissa; T Assimes; P Ernst
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

8.  Hypokalaemia in healthy volunteers after single and multiple doses of formoterol or salbutamol.

Authors:  B T van den Berg; R T Louwerse; G J Luiken; R E Jonkers; C J van Boxtel
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

9.  Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.

Authors:  Christopher I Whale; Milind P Sovani; Kevin J Mortimer; Timothy W Harrison; Anne E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  2008-04-03       Impact factor: 4.335

10.  A comparative study of efficacy and safety of arformoterol and salbutamol nebulization as rescue therapy in acute non-severe asthma.

Authors:  Sibes K Das; Indranil Biswas; Arun K Bandyopadhyay; Tapan D Bairagya; Somnath Bhattacharya
Journal:  Indian J Pharmacol       Date:  2011-07       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.